Geroscience is a research paradigm based in understanding the genetic, molecular and cellular mechanisms that make aging a major risk factor for and driver of common chronic conditions and diseases of older people. Geroscience research seeks to understand how aging affects the disease process and to use that knowledge to slow the rate of aging, reverse its effects, and delay or even cure age-related diseases.
The Translational Geroscience Network (TGN) is a collaboration of researchers looking at clinical interventions that target fundamental mechanisms of aging to delay, prevent or treat age-related diseases and disabilities as a group, instead of one at a time.
Network Clinical Trials
The Translational Geroscience Network (TGN) maintains this list of clinical trials in which the network is directly involved. This list, including most of its section headers, are dynamically updated with detail by clinicaltrials.gov to showcase the Network's progress, collaboration, and expansion. This list can be searched or exported as a spreadsheet.
| NCT # | Title | Acronym | Status | Publications | Stored Specimens | Conditions | Interventions | Outcome Measures | Sponsor Collaborators | Gender | Age | Phases | Enrollment | Funded Bys | Study Type | Study Designs | Other IDs | Start Date | Primary Completion Date | Completion Date | First Posted | Results First Posted | Last Update Posted | Locations | Study Documents | URL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04785300 | ALSENLITE: Senolytics for Alzheimer's Disease | Enrolling by invitation | PMID: 34366147 | Mild Cognitive Impairment|Alzheimer Disease | Drug: Dasatinib|Drug: Quercetin | Safety and Tolerability of 11 week of intermittent D+Q treatment | James L. Kirkland, MD, PhD|Mayo Clinic | All | 55 Years and older (Adult, Older Adult) | Phase 1|Phase 2 | 20 | Other | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 19-003394 | July 6, 2022 | December 2023 | December 2023 | March 5, 2021 | January 19, 2023 | Mayo Clinic in Rochester, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT04785300 | ||||
| NCT04733534 | An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer | Recruiting | Frailty|Childhood Cancer | Drug: Dasatinib plus Quercetin|Drug: Fisetin | Change in walking speed|Change in Walking Speed|Senescent cell abundance in blood (p16INK4A)|Safety of two different senolytic therapies as assessed by treatment-related adverse events using CTCAE v5.0|Tolerability of two different senolytic therapies as assessed by treatment-related adverse events using CTCAE v5.0 | St. Jude Children's Research Hospital|National Institutes of Health (NIH)|National Cancer Institute (NCI) | All | 18 Years and older (Adult, Older Adult) | Phase 2 | 60 | Other|NIH | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | SENSURV|U01CA246510 | June 6, 2022 | July 2023 | July 2024 | February 2, 2021 | June 9, 2022 | St. Jude Children's Research Hospital, Memphis, Tennessee, United States | https://ClinicalTrials.gov/show/NCT04733534 | |||||
| NCT04537299 | COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes | COVID-FIS | Enrolling by invitation | PMID: 34375437 | Covid19|SARS-CoV Infection | Drug: Fisetin|Drug: Placebo | Change in COVID-19 Severity | Mayo Clinic|National Institute on Aging (NIA) | All | 65 Years and older (Older Adult) | Phase 2 | 150 | Other|NIH | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | 20-008867|1R01AG072301-01 | January 25, 2022 | December 2023 | December 2023 | September 3, 2020 | January 25, 2023 | Mayo Clinic, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT04537299 | |||
| NCT04476953 | COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation | Enrolling by invitation | Covid19 | Drug: Placebo|Drug: Fisetin | Serious Adverse Events|Change in oxygenation status|CoV Severity Category | Mayo Clinic | All | 18 Years and older (Adult, Older Adult) | Phase 2 | 80 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | 20-003936 | August 3, 2020 | September 2023 | September 2023 | July 20, 2020 | January 25, 2023 | Mayo Clinic in Rochester, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT04476953 | |||||
| NCT04313634 | Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans | Recruiting | Healthy | Drug: Dasatinib|Drug: Quercetin|Drug: Fisetin | Percent Changes in C-terminal telopeptide of type I collagen [CTX]|Percent Changes in amino-terminal propeptide of type I collagen [P1NP] | Sundeep Khosla, M.D.|Mayo Clinic | Female | 70 Years and older (Older Adult) | Phase 2 | 120 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care | 18-010546 | June 9, 2020 | April 2023 | April 2023 | March 18, 2020 | July 26, 2022 | Mayo Clinic in Rochester, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT04313634 | |||||
| NCT04176133 | Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination | Completed | Healthy | Drug: Entolimod|Drug: Placebo | Immunogenicity|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Mayo Clinic|Genome Protection, Inc | All | 65 Years and older (Older Adult) | Phase 2 | 61 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention | 19-004847 | October 30, 2019 | March 30, 2022 | March 30, 2022 | November 25, 2019 | May 3, 2022 | Mayo Clinic in Rochester, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT04176133 | |||||
| NCT04063124 | Senolytic Therapy to Modulate Progression of Alzheimer's Disease | SToMP-AD | Completed | PMID: 34687726 PMID: 35098970 | Alzheimer Disease | Drug: Dasatinib + Quercetin | Brain Penetrance of Dasatinib (D)|Brain Penetrance of Quercetin (Q)|Alzheimer's Disease Marker - CSF Tau|Alzheimer's Disease Marker - CSF Amyloid Beta|Senescence Marker IL-6 in CSF|Senescence Marker P16 in CSF|Electronic Gait Mapping Under Single and Dual-task Conditions|Montreal Cognitive Assessment (MoCA) | The University of Texas Health Science Center at San Antonio|Mayo Clinic | All | 65 Years and older (Older Adult) | Phase 1|Phase 2 | 5 | Other | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | HSC20190222H | February 14, 2020 | December 10, 2021 | January 30, 2023 | August 21, 2019 | March 6, 2023 | March 6, 2023 | Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, San Antonio, Texas, United States | "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/24/NCT04063124/Prot_SAP_000.pdf | https://ClinicalTrials.gov/show/NCT04063124 | |
| NCT03675724 | Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults | AFFIRM-LITE | Recruiting | Frail Elderly Syndrome | Dietary Supplement: Fisetin|Drug: Placebo oral capsule | Decrease in blood inflammation markers | Mayo Clinic | All | 70 Years and older (Older Adult) | Phase 2 | 40 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | 18-007332 | November 15, 2018 | June 2024 | June 2024 | September 18, 2018 | January 26, 2023 | Mayo Clinic in Rochester, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT03675724 | ||||
| NCT04235309 | Physical Resilience: Indicators and Mechanisms in the Elderly (PRIME) Collaborative Phase 2 | PRIME-Knee | Recruiting | Resilience|Aging | Change in musculoskeletal resiliency following orthopedic surgery as measured by physical activity (step counts)|Change in musculoskeletal resiliency following orthopedic surgery as measured by Lower Extremity Physical Activities of Daily Living (LE PADLs)|Change in musculoskeletal resiliency following orthopedic surgery as measured by PROMIS Pain Intensity|Change in musculoskeletal resiliency following orthopedic surgery as measured by PROMIS Pain Interference|Change in cognitive resiliency following orthopedic surgery as measured by 3D-CAM.|Change in cognitive resiliency following orthopedic surgery as measured by cognitive change index (CCI) for patient.|Change in cognitive resiliency following orthopedic surgery as measured by cognitive change index (CCI) for informant about patient.|Change in association between in vitro immune resiliency and resilient outcomes following elective orthopedic surgery.|Change in dual task gait speed|Change in tissue oxygenation index (TOI)|Intraoperative electrocardiography (ECG) RR variability | Duke University|National Institute on Aging (NIA) | All | 60 Years and older (Adult, Older Adult) | 250 | Other|NIH | Observational | Observational Model: Cohort|Time Perspective: Prospective | Pro00103483|4UH3AG056925-03 | February 27, 2020 | February 27, 2023 | February 27, 2023 | January 21, 2020 | February 21, 2022 | Duke Regional Hospital, Durham, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Durham University Medical Center, Durham, North Carolina, United States | https://ClinicalTrials.gov/show/NCT04235309 | ||||||
| NCT03430037 | Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women | AFFIRM | Recruiting | Frail Elderly Syndrome | Dietary Supplement: Fisetin|Drug: Placebo oral capsule | Improved 6 minute walk | Mayo Clinic | Female | 70 Years and older (Older Adult) | Phase 2 | 40 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | 17-000472 | February 6, 2018 | June 2024 | June 2024 | February 12, 2018 | January 26, 2023 | Mayo Clinic in Rochester, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT03430037 | ||||
| NCT03325322 | Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease | Enrolling by invitation | Chronic Kidney Diseases|Diabetes Mellitus|Diabetic Nephropathies | Dietary Supplement: Fisetin|Drug: Placebo oral capsule | Change in inflammatory markers including C-reactive protein|Effect on Mesenchymal stem cell function including cell migration|Effect on measures of Frailty including Fried Criteria|Kidney function including estimated glomerular filtration rate|Kidney function including urine protein excretion rate|Number of participants with treatment-related adverse events including hospitalization | Mayo Clinic | All | 40 Years to 80 Years (Adult, Older Adult) | Phase 2 | 30 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment | 16-010521 | January 2, 2018 | December 2025 | December 2026 | October 30, 2017 | November 10, 2022 | Mayo Clinic in Rochester, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT03325322 | |||||
| NCT02874989 | Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial | IPF | Completed | PMID: 30616998 | Idiopathic Pulmonary Fibrosis (IPF) | Drug: Dasatinib + Quercetin|Drug: Placebo | Percentage of pro-inflammatory expressing cells|Blood Pressure|Weight|Heart Rate|CBC (complete blood count)|Lipid Panel|HbA1c (glycated hemoglobin)|CMP (comprehensive metabolic panel)|Plasma hsCRP (high-sensitivity C-reactive protein)|Plasma IL-6 (inflammatory biomarker)|Plasma IL-6R (inflammatory biomarker)|Plasma PASP biomarkers (inflammatory biomarkers)|p16INK4a biomarker (inflammatory biomarker) | Wake Forest University Health Sciences|Mayo Clinic|The University of Texas Health Science Center at San Antonio | All | 50 Years and older (Adult, Older Adult) | Phase 1 | 26 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science | IRB00037000 | December 16, 2016 | June 3, 2019 | June 3, 2019 | August 22, 2016 | May 12, 2020 | Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|University of Texas Health Science Center, San Antonio, Texas, United States | "Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02874989/ICF_000.pdf | https://ClinicalTrials.gov/show/NCT02874989 | ||
| NCT02848131 | Senescence in Chronic Kidney Disease | Enrolling by invitation | PMID: 31542391 PMID: 35615688 | Chronic Kidney Disease | Drug: Group 2: Dasatinib|Drug: Group 2: Quercetin | Change in proportion of senescent cells (representing the total senescent cell burden) present|Change in proportion of senescent mesenchymal stem cells present|Change in mesenchymal stem cell function|Change in Frailty index score|Change in kidney function | Mayo Clinic | All | 40 Years to 80 Years (Adult, Older Adult) | Phase 2 | 30 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 15-005843 | July 2016 | April 2023 | April 2023 | July 28, 2016 | May 17, 2022 | Mayo Clinic in Rochester, Rochester, Minnesota, United States | "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02848131/Prot_SAP_001.pdf | https://ClinicalTrials.gov/show/NCT02848131 | |||
| NCT02652052 | Hematopoietic Stem Cell Transplant Survivors Study | Recruiting | Stem Cell Transplant | Other: Standard of Care - Observation Only|Drug: Group 2: Quercetin|Drug: Group 2: Dasatinib | Frailty | Mayo Clinic | All | 18 Years and older (Adult, Older Adult) | Not Applicable | 10 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care | 15-004683|NCI-2021-14235 | March 1, 2016 | October 15, 2023 | October 15, 2024 | January 11, 2016 | January 23, 2023 | Mayo Clinic in Rochester, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT02652052 | |||||
| NCT04771611 | COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications | COVFIS-HOME | Enrolling by invitation | Covid19|Coronavirus Infection | Drug: Fisetin | Serious Adverse Events|Long Hauler Syndrome | James L. Kirkland, MD, PhD|Mayo Clinic | All | 18 Years and older (Adult, Older Adult) | Phase 2 | 150 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | 20-009705 | July 14, 2021 | May 2023 | May 2023 | February 25, 2021 | January 18, 2023 | Mayo Clinic, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT04771611 | ||||
| NCT04685590 | Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study | SToMP-AD | Recruiting | PMID: 34366147 PMID: 34687726 | Alzheimer Disease, Early Onset|Mild Cognitive Impairment | Drug: Dasatinib + Quercetin|Other: Placebo Capsules | Serious Adverse Events (SAEs) and Adverse Events (AEs) in treatment group as compared to placebo group|Change in cellular senescence blood marker Senescence-Associated Secretory Phenotype (SASP) composite score|Change in cellular senescence blood marker Cluster of Differentiation 3 (CD3) in blood|Change in cellular senescence blood marker cyclin-dependent kinase inhibitor 2A (p16INK4A+) in blood|Change in cellular senescence blood marker T cells in blood|Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) slope|Change in the 14 - item Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog 14) slope|Change in Positron Emission Tomography (PET) - Computed Tomography (CT) - brain tau pathology | Wake Forest University Health Sciences|The University of Texas Health Science Center at San Antonio | All | 65 Years and older (Older Adult) | Phase 2 | 48 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | IRB00067429 | December 22, 2021 | January 2027 | January 2032 | December 28, 2020 | December 23, 2022 | Wake Forest Health Sciences, Winston-Salem, North Carolina, United States | https://ClinicalTrials.gov/show/NCT04685590 | |||
| NCT04210986 | Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial | Active, not recruiting | Osteoarthritis, Knee | Dietary Supplement: Fisetin|Drug: Placebo oral capsule | Incidence of Treatment-Emergent Adverse Events as assessed by blood chemistries (Liver)|Incidence of Treatment-Emergent Adverse Events as assessed by blood chemistries (Kidney)|Incidence of Treatment-Emergent Adverse Events as assessed by blood chemistries (Lysis Syndrome)|Change in levels of pro-inflammatory markers associated with Senescence|Change in levels of cartilage degenerating markers associated with OA|Change in physical function of the Study Knee (6 min walk)|Change in physical function of the Study Knee (timed-up-and-go test)|Change in physical function of the Study Knee (fast 40-meter walk)|Change in physical function of the Study Knee (LEK)|Change in physical function of the Study Knee (Chair Test)|Change in muscle strength (Isokinetic Dynamometry)|Evaluation of patient reported outcomes (PROs) for knee pain|Evaluation of patient reported outcomes (PROs) for knee function|Change in the quality of articular cartilage in the Study Knee with quantitative magnetic resonance imaging (MRI)|Change in time to conversion to alternative treatment | Steadman Philippon Research Institute|United States Department of Defense|Office of Naval Research (ONR) | All | 40 Years to 80 Years (Adult, Older Adult) | Phase 1|Phase 2 | 100 | Other|U.S. Fed | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | 2019-16 | January 6, 2020 | December 1, 2022 | December 1, 2022 | December 26, 2019 | October 17, 2022 | The Steadman Clinic, Vail, Colorado, United States | https://ClinicalTrials.gov/show/NCT04210986 |
* All data provided by clinicaltrials.gov except publication and stored specimen columns. Data display last updated on Mar 27, 2023 6:00:00 AM